Recent discussions on X about Rocket Pharmaceuticals (RCKT) have been buzzing with excitement following the announcement that the FDA has lifted a clinical hold on the company's pivotal Phase 2 trial for RP-A501, a gene therapy for Danon disease. Many users are highlighting the significant pre-market stock surge of over 20%, viewing it as a major milestone for the biotech firm. The news has sparked conversations about the potential impact on the company's future in rare disease treatments.
While optimism dominates, some voices on X are tempering expectations, noting that clinical trials still carry inherent risks despite this positive development. Posts are circulating about the technical patterns in the stock's chart, with some suggesting a breakout could be imminent if momentum continues. This mix of enthusiasm and caution reflects the high stakes surrounding Rocket Pharmaceuticals' next steps.
Note: This discussion summary was generated from an AI condensation of post data.
Rocket Pharmaceuticals Insider Trading Activity
Rocket Pharmaceuticals insiders have traded $RCKT stock on the open market 20 times in the past 6 months. Of those trades, 2 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $RCKT stock by insiders over the last 6 months:
- KINNARI PATEL (See Remarks) has made 1 purchase buying 21,099 shares for an estimated $99,165 and 3 sales selling 8,254 shares for an estimated $78,447.
- GAURAV SHAH (CEO) has made 1 purchase buying 20,000 shares for an estimated $101,600 and 2 sales selling 5,874 shares for an estimated $38,160.
- JONATHAN DAVID SCHWARTZ (See Remarks) has made 0 purchases and 4 sales selling 20,076 shares for an estimated $118,294.
- MARTIN WILSON (General Counsel) has made 0 purchases and 3 sales selling 13,642 shares for an estimated $46,516.
- AARON ONDREY (Chief Financial Officer) has made 0 purchases and 2 sales selling 8,966 shares for an estimated $43,903.
- JOHN MILITELLO (See Remarks) has made 0 purchases and 4 sales selling 8,773 shares for an estimated $32,979.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Rocket Pharmaceuticals Hedge Fund Activity
We have seen 118 institutional investors add shares of Rocket Pharmaceuticals stock to their portfolio, and 160 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 12,626,491 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $30,934,902
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 4,820,701 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $11,810,717
- JANUS HENDERSON GROUP PLC removed 3,255,590 shares (-98.9%) from their portfolio in Q2 2025, for an estimated $7,976,195
- MAVERICK CAPITAL LTD added 3,164,595 shares (+60.9%) to their portfolio in Q2 2025, for an estimated $7,753,257
- MPM BIOIMPACT LLC added 2,284,816 shares (+141.2%) to their portfolio in Q2 2025, for an estimated $5,597,799
- NEWTYN MANAGEMENT, LLC added 2,000,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $4,900,000
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,943,853 shares (-63.9%) from their portfolio in Q2 2025, for an estimated $4,762,439
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Rocket Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $RCKT in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 08/20/2025
- Cantor Fitzgerald issued a "Overweight" rating on 08/08/2025
- Canaccord Genuity issued a "Buy" rating on 07/25/2025
- UBS issued a "Buy" rating on 06/17/2025
- BMO Capital issued a "Outperform" rating on 05/28/2025
- Scotiabank issued a "Sector Outperform" rating on 05/28/2025
- Wedbush issued a "Outperform" rating on 05/16/2025
To track analyst ratings and price targets for Rocket Pharmaceuticals, check out Quiver Quantitative's $RCKT forecast page.
Rocket Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $RCKT recently. We have seen 14 analysts offer price targets for $RCKT in the last 6 months, with a median target of $9.5.
Here are some recent targets:
- Geulah Livshits from Chardan Capital set a target price of $11.0 on 08/20/2025
- Josh Schimmer from Cantor Fitzgerald set a target price of $8.0 on 08/08/2025
- Whitney Ijem from Canaccord Genuity set a target price of $10.0 on 07/25/2025
- Greg Harrison from B of A Securities set a target price of $4.0 on 07/25/2025
- Colin Bristow from UBS set a target price of $5.0 on 06/17/2025
- Andrew Tsai from Jefferies set a target price of $2.5 on 05/28/2025
- Kostas Biliouris from BMO Capital set a target price of $8.0 on 05/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
